A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PROVE-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 31 Oct 2016 Planned number of patients changed from 1000 to 830.
- 31 Oct 2016 Status changed from not yet recruiting to recruiting.